Cytek's Revenue Grows While Net Losses Expand
In its second-quarter report for fiscal year 2026, Cytek Biosciences (NASDAQ:CTKB) showed strong revenue growth and an expanding installed base of instruments. Total revenue reached $48.1 million, up from the previous year, driven by increased sales in both new hardware and recurring service and reagent income. The company's gross profit also improved significantly due to higher margins and a one-time tariff refund. Despite these positive financial indicators, Cytek’s net loss more than doubled compared to last year, reaching $12.2 million. Operating expenses rose by 15%, driven primarily by litigation costs, severance, and increased R&D spending. Adjusted EBITDA turned negative at a $1.5 million loss for the quarter. The company's cash reserves remained stable at around $262 million, indicating that its balance sheet is not yet under pressure from rising expenses. Institutional interest in Cytek has also grown, with 26 hedge funds now holding positions compared to 18 previously.
Topics: ebitda installed_base loss_expansion product_launch revenue_growth